MetaCap

Celldex Therapeutics (CLDX) vs Achieve Life Sciences (QUIT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celldex Therapeutics is the larger company by market cap ($2.15 billion vs $573.2 million), about 3.8 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLDX-34.59%QUIT-25.87%
+16%-10%-37%
Aug 17, 20261 yearNov 20, 2026
CLDX-32.10%QUIT-30.41%
+8%-13%-34%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLDX versus QUIT key metrics
MetricCLDXQUIT
Share price$27.42$5.56
Market cap$2.15B$573.25M
1-day change-1.93%-5.28%
YTD return+0.96%—
1-year return+5.79%—
5-year return-30.78%—
EPS (TTM)$-4.29$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.54M—
Revenue growth (YoY)-77.99%—
Net income (latest FY)$-258.76M$-54.65M
Gross margin87.06%—
Operating margin-18599.81%—
Net margin-16748.03%—
52-week high$45.14$8.64
52-week low$22.33$2.62
Distance from 52-week high-39.26%-35.65%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+133.41%+162.23%
Average volume1.33M1.38M
Shares outstanding78.55M103.10M
Employees19828
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Celldex Therapeutics is about 3.8 times larger than Achieve Life Sciences by market value ($2.15B vs $573.25M).

About Celldex Therapeutics

CLDX stock →

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees

About Achieve Life Sciences

QUIT stock →

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees

CLDX vs QUIT FAQ

Which is bigger, Celldex Therapeutics or Achieve Life Sciences?

Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.15B compared with $573.25M for Achieve Life Sciences (QUIT).

Are Celldex Therapeutics and Achieve Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons